share_log

天坛生物(600161.SH):下属企业药品终止临床试验

Beijing Tiantan Biological Products Corporation (600161.SH): Subsidiary company's Pharmaceutical clinical trials have been terminated.

Gelonghui Finance ·  Dec 27, 2024 17:02

Gelonghui, December 27丨Beijing Tiantan Biological Products Corporation (600161.SH) announced that its subsidiary, China National Pharmaceutical Group Wuhan Biological Products Co., Ltd., has developed the "Intravenous COVID-19 Human Immunoglobulin (pH 4)" which is currently in the Phase II clinical trial research stage. Recently, after comprehensive assessment, the company has decided to terminate the Phase II clinical trial research and subsequent development of this drug.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment